BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gardner SD, Kim J, Baptiste-Brown S, Lopez V, Hamatake R, Gan J, Edwards S, Elko-Simms L, Dumont EF, Leivers M, Hong Z, Paff MT. GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects. J Viral Hepat 2018;25:19-27. [PMID: 28692182 DOI: 10.1111/jvh.12753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Z, Zhang J, Zhou E, Ren C, Wang J, Wang Y. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. Eur J Med Chem 2022;240:114595. [PMID: 35868125 DOI: 10.1016/j.ejmech.2022.114595] [Reference Citation Analysis]
2 van Hoogdalem EJ, van Iersel MT, Winter E, Constant J, Kappler M. Pharmacology-Guided Rule-Based Adaptive Dose Escalation in First-in-Human Studies. Clin Pharmacol Ther 2021;109:1326-33. [PMID: 33150581 DOI: 10.1002/cpt.2101] [Reference Citation Analysis]
3 Deng Y, Campbell F, Han K, Theodore D, Deeg M, Huang M, Hamatake R, Lahiri S, Chen S, Horvath G, Manolakopoulos S, Dalekos GN, Papatheodoridis G, Goulis I, Banyai T, Jilma B, Leivers M. Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. J Viral Hepat 2020;27:699-708. [PMID: 32096313 DOI: 10.1111/jvh.13282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Becica J, Hruszkewycz DP, Steves JE, Elward JM, Leitch DC, Dobereiner GE. High-Throughput Discovery and Evaluation of a General Catalytic Method for N-Arylation of Weakly Nucleophilic Sulfonamides. Org Lett 2019;21:8981-6. [PMID: 31651171 DOI: 10.1021/acs.orglett.9b03380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chong PY, Shotwell JB, Miller J, Price DJ, Maynard A, Voitenleitner C, Mathis A, Williams S, Pouliot JJ, Creech K, Wang F, Fang J, Zhang H, Tai VW, Turner E, Kahler KM, Crosby R, Peat AJ. Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor. J Med Chem 2019;62:3254-67. [PMID: 30763090 DOI: 10.1021/acs.jmedchem.8b01719] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
6 Arrington K, Barcan GA, Calandra NA, Erickson GA, Li L, Liu L, Nilson MG, Strambeanu II, VanGelder KF, Woodard JL, Xie S, Allen CL, Kowalski JA, Leitch DC. Convergent Synthesis of the NS5B Inhibitor GSK8175 Enabled by Transition Metal Catalysis. J Org Chem 2019;84:4680-94. [PMID: 30339385 DOI: 10.1021/acs.joc.8b02269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]